Literature DB >> 26011138

Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.

Joseph Hong1, Lynne C Krop1, Tracy Johns2,3, Manjunath P Pai4.   

Abstract

STUDY
OBJECTIVE: To compare the likelihood of vancomycin target trough concentration attainment based on infectious diagnosis and/or minimum inhibitory concentration for the organism by using a two-sample approach versus the prior institutional standard of a trough-only approach in obese patients receiving vancomycin.
DESIGN: Preintervention and postintervention study.
SETTING: Community acute care hospital. PATIENTS: One hundred fifty hospitalized adults with a body mass index (BMI) of 30 kg/m(2) or greater and treated with vancomycin for at least 48 hours between July 2013 and March 2014 were evaluated to compare the frequency of steady-state therapeutic trough concentration attainment between two approaches: a trough-only dosing method (preintervention group [75 patients]) and a dosing strategy measuring two vancomycin serum concentrations during the elimination phase (peak and trough) to calculate pharmacokinetic parameters and individualize the maintenance regimen (postintervention group [75 patients]). Data for the preintervention group were retrospectively retrieved from a 4-month period for patients admitted between July and October 2013, prior to implementation of the two-point vancomycin dosing protocol. Initial vancomycin empiric dose selection for both groups utilized the same population-based pharmacokinetic equations.
MEASUREMENTS AND MAIN RESULTS: Median (5th-95th percentile) age, weight, and BMI were 59 (34-80) years, 105 (79.8-164) kg, and 34.5 (30.0-55.1) kg/m(2) , respectively, for all patients. The percentages of initial therapeutic trough concentrations achieved in the preintervention and postintervention groups were 32.0% and 42.7%, respectively (p=0.117). For patients with a second trough measurement, 31.0% in the preintervention group and 65.2% in the postintervention group were within the therapeutic range (p=0.024).
CONCLUSION: Measurement of two serum vancomycin concentrations significantly improves subsequent target trough concentration attainment in the obese population.
© 2015 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  clinical pharmacy services; dosing strategies; obese; obesity; therapeutic drug monitoring; vancomycin; weight

Mesh:

Substances:

Year:  2015        PMID: 26011138     DOI: 10.1002/phar.1588

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.

Authors:  Manjunath P Pai; Joseph Hong; Lynne Krop
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.

Authors:  Joseph J Carreno; Ben Lomaestro; John Tietjan; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Vancomycin: Audit of American guideline-based intermittent dose administration with focus on overweight patients.

Authors:  Mari Koyanagi; Rebecca Anning; Mark Loewenthal; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2020-01-22       Impact factor: 4.335

4.  New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.

Authors:  Stefano Cristallini; Maya Hites; Hakim Kabtouri; Jason A Roberts; Marjorie Beumier; Frederic Cotton; Jeffrey Lipman; Frédérique Jacobs; Jean-Louis Vincent; Jacques Creteur; Fabio Silvio Taccone
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

6.  Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study.

Authors:  Sang-Mi Kim; Hyun-Seung Lee; Na-Young Hwang; Kyunga Kim; Hyung-Doo Park; Soo-Youn Lee
Journal:  Drug Des Devel Ther       Date:  2021-03-04       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.